Aktive stoffer, hvis plasmakoncentration kan ændres af dasatinib Samtidig brug af dasatinib og et CYP3A4- substrat kan øge eksponeringen af CYP3A4- substratet.
Active substances that may have their plasma concentrations altered by dasatinib Concomitant use of dasatinib and a CYP3A4 substrate may increase exposure to the CYP3A4 substrate.